CPhI Announces US-Market Report at InformEx - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

CPhI Announces US-Market Report at InformEx

CPhI Worldwide announced the launch of the CPhI Pharma InsightsUSA market report, a joint venture with InformEx, which will provide European perspectives on the accessibility, growth, and export market in the United States. The report is designed to encourage and increase trade harmonization between the two major pharma economies of the world, the sponsors say.

The US country report, which will be distributed in July 2014, follows the launch of the CPhI annual report (released at CPhI Worldwide, Frankfurt, October 2013). The new report, which analyzes current and future trends across the US pharma landscape, will feature expert opinion from Europe’s leading companies, contrasted with US internal perceptions to provide a holistic view of the major trade flows within the region, according to report sponsors.

The report will examine the areas in which European companies are looking to work with US counterparts, import into the US and, domestic and export manufacturing across pharma’s fine, specialty, and custom chemicals market.

Following last year’s report, which covered the global industry, CPhI will now examine trends within specific leading pharma economies.

Source: CPhI




blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here